title: Chronic myeloid leukemia as a secondary malignancy after diffuse large B-cell lymphoma.
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, Cancer Center Dongnam Institute Radiological and Medical Sciences, Busan, Korea.
authors.forename: Ha-young
authors.initials: HY
authors.lastname: Lee
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
authors.forename: Kyung Hee
authors.initials: KH
authors.lastname: Lee
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
authors.forename: Myung Soo
authors.initials: MS
authors.lastname: Hyun
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
authors.forename: Min Kyoung
authors.initials: MK
authors.lastname: Kim
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
authors.forename: Sung Ae
authors.initials: SA
authors.lastname: Koh
authors.affiliation: Department of Laboratory Medicine, Yeungnam University College of Medicine, Daegu, Korea.
authors.forename: Hee Soon
authors.initials: HS
authors.lastname: Cho
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use; D001856:Bone Marrow Examination; D059248:Chemoradiotherapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D000068877:Imatinib Mesylate; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D008297:Male; D016609:Neoplasms, Second Primary; D010879:Piperazines / Q000627:therapeutic use; D049268:Positron-Emission Tomography; D011239:Prednisolone / Q000008:administration & dosage; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage; D051598:Whole Body Imaging / Q000379:methods
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D014750:Vincristine; D004317:Doxorubicin; D000068877:Imatinib Mesylate; D003520:Cyclophosphamide; D011239:Prednisolone
keywords: Chronic myeloid leukemia; Diffuse large B-cell lymphoma; Therapy-related